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Abstract
Objective To assess the cost-effectiveness of a mobile health-supported lifestyle intervention compared with usual care.
Methods We conducted a cost-effectiveness analysis from the perspective of the publicly-funded health care system. We
estimated costs associated with the intervention and health care utilisation from first antenatal care appointment through
delivery. We used bootstrap methods to quantify the uncertainty around cost‐effectiveness estimates. Health outcomes
assessed in this analysis were gestational weight gain (GWG; kg), incidence of excessive GWG, quality-adjusted life years
(QALYs), and incidence of large-for-gestational-age (LGA). Incremental cost-effectiveness ratios (ICERs) were calculated
as cost per QALY gained, cost per kg of GWG avoided, cost per case of excessive GWG averted, and cost per case of LGA
averted.
Results Total mean cost including intervention and health care utilisation was €3745 in the intervention group and €3471 in
the control group (mean difference €274, P= 0.08). The ICER was €2914 per QALY gained. Assuming a ceiling ratio of
€45,000, the probability that the intervention was cost‐effective based on QALYs was 79%. Cost per kg of GWG avoided
was €209. The cost-effectiveness acceptability curve (CEAC) for kg of GWG avoided reached a confidence level of 95% at
€905, indicating that if one is willing to pay a maximum of an additional €905 per kg of GWG avoided, there is a 95%
probability that the intervention is cost-effective. Costs per case of excessive GWG averted and case of LGA averted were
€2117 and €5911, respectively. The CEAC for case of excessive GWG averted and for case of LGA averted reached a
confidence level of 95% at €7090 and €25,737, respectively.
Conclusions Results suggest that a mobile-health lifestyle intervention could be cost-effective; however, a better under-
standing of the short- and long-term costs of LGA and excessive GWG is necessary to confirm the results.
Introduction
Poor diet and exercise during pregnancy can result in
excessive gestational weight gain (GWG) and the onset of
glucose intolerance known as gestational diabetes mellitus
(GDM) [1]. Excessive GWG and GDM are associated with
costly short- and long-term outcomes for the pregnant
woman and her infant. Excessive GWG is associated with
increased risk of preterm delivery, as well as large-for-
gestational-age (LGA) and macrosomic infants [2, 3].
Excessive GWG has also been associated with both an
increased risk of early childhood obesity [4, 5] and an
increase in maternal body mass index (BMI) [6]. This is of
concern because obesity is consistently cited as a significant
contributor to the global burden of disease and places a
significant economic burden on health care systems [7].
Risks for mothers and infants, as well as increased costs
to the health care system, have provided the impetus for
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investigators to develop cost-effective interventions to
improve diet and exercise and reduce excessive weight
gained during pregnancy. This is particularly important
among women with an elevated BMI, for whom health
service usage and costs during pregnancy are increased by
23% and 37%, respectively [8], and whose children also
incur higher health care costs over their first 18 years of life
[9]. A range of lifestyle interventions that promote dietary
and physical activity changes have been developed and
tested; systematic reviews of the effectiveness of these
interventions have concluded that they may be successful at
reducing weight gained during pregnancy and risk of pre-
term birth [10, 11]; however, little is known regarding how
cost-effective these interventions are from the perspective of
the health care system.
The objective of this study is to conduct a cost-
effectiveness analysis to evaluate the costs and con-
sequences of providing a mobile health-supported lifestyle
intervention to women with an elevated BMI. To our
knowledge, this is the first study to examine the cost-
effectiveness of using a mobile-phone app to improve




The Pregnancy, Exercise And nutrition Research Study
(PEARs) was a single-centre randomised controlled trial
conducted within The National Maternity Hospital, Dublin,
Ireland; it is registered with Current Controlled Trials
(ISRCTN 29316280) and institutional ethical approval was
obtained. Participants provided written informed consent. A
detailed description of this trial has been published [12, 13].
Briefly, women (n= 565) were recruited at their first
antenatal appointment, between 10- and 15-weeks’ gesta-
tion. Women with a BMI of ≥25 kg/m2 and ≤39.9 kg/m2
were eligible to participate if they were between 18 and 45
years of age, with a singleton pregnancy, and owned a
smartphone. Women were excluded if they had experienced
GDM in a previous pregnancy, had any illness requiring
medical treatment or were unable to provide informed
written consent.
Description of the intervention
The aim of the PEARs trial was to assess whether a ‘healthy
lifestyle package,’ including dietary and exercise advice and
a smartphone app to reinforce health messages, would
reduce the incidence of GDM. Secondary aims included
limiting GWG to within the BMI-specific Institute of
Medicine (IOM) recommendations [14], and reducing the
incidence of infants born LGA. Incidence of GDM was
assessed at 28 weeks’ gestation by an oral glucose tolerance
test, total GWG was calculated as the last measured weight
between 36 weeks’ gestation and delivery minus the weight
at the first appointment, and incidence of LGA was defined
as birthweight centile >90th centile using GROW centiles
[15]. Alongside three visits reinforcing messages about
healthy eating and exercise, all women in the intervention
group were provided with a smartphone app, where they
could find recipes, exercise tips and a ‘tip of the day.’ The
control group received standard care.
Economic evaluation
The economic evaluation was conducted from the per-
spective of the publicly-funded health and social care sys-
tem in Ireland. Analysis was performed by intention-to-treat
using all available cases. Costs were calculated from time of
first antenatal care appointment through delivery. Unit costs
for outpatient visits associated with providing the inter-
vention were calculated based on the amount of time visits
took, the health care provider involved, and the average
salary of that health care provider, taken from the 2017 Irish
Health Service Executive (HSE) salary scales [16]. Total
staff costs were adjusted to include social insurance, pen-
sion, and overheads, as recommended by the Guidelines for
the Economic Evaluation of Health Technologies in Ireland
(Table S1) [17]. Number of antenatal admissions and unit
costs for medical care associated with antenatal admissions
and delivery were derived from Diagnosis-Related Groups
(DRGs), recorded by the Hospital In-Patient Enquiry
(HIPE) department. After each episode, staff from the HIPE
department review patients’ charts and input all medical
interventions, medications, and visits from health care
professionals into their computer system. An algorithm
processes this information and assigns each antenatal
admission or delivery episode a DRG code, along with the
number of days spent in hospital. We obtained these data
for each patient in our sample and matched them to the
estimated cost per DRG (adjusted for length of stay) that is
provided in the HSE Ready Reckoner [18]. Costs provided
in the Ready Reckoner are calculated as national averages
adjusted to take account of hospital variation. We used these
costs to estimate the cost of care for participants in both the
intervention and control groups. All hospitals in the Irish
health system are currently transitioning to a model of
funding that allocates resources to hospitals based on
average prices for DRGs (known as “Activity-Based
Funding”) [19], and is therefore a relevant way of esti-
mating costs in an economic evaluation. Costs of develop-
ing the mobile health application were included as in the
future the technology would need to be upgraded and re-
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designed to be context-specific; these costs included pro-
gramming development on both Android and Apple plat-
forms, as well as 30 hours of clinical nutritionist time to
develop content. No discounting was applied as the time to
follow-up was <1 year. Analyses were conducted in R
version 3.5.1 and Stata version 15.1 The code is available
upon request.
Outcomes
A core outcome set for studies on obesity in pregnant
patients does not yet exist; a protocol describing a study for
its development has recently been published [20]. The
health outcomes used in this analysis were GWG (kg),
incidence of GWG exceeding IOM guidelines, quality-
adjusted life years (QALYs), and incidence of LGA. For
binary outcomes, two-sample tests of proportions were
used. For continuous outcomes and costs, two-sample t tests
were used. Previous analyses of the PEARs trial considered
a wide range of primary and secondary outcomes and
applied an adjustment for multiple hypothesis testing [13];
in this paper we use a limited set of outcomes, chosen to
facilitate comparison with other published studies, and do
not adjust for multiple outcomes. We do not explore the
cost-effectiveness of the PEARs trial for reducing the
incidence of GDM as there was no difference in incidence
between the intervention and control groups.
The PEARs trial did not measure QALYs directly. To
obtain a measure of QALYs, we converted kilograms of
GWG to the expected number of QALYs lost. We applied
an analysis from a 2009 IOM report that estimates expected
QALYs lost due to outcomes of infant mortality, post-
partum weight retention and childhood obesity for each
maternal BMI category and value of GWG [21]. Using a
range of epidemiological data, the IOM analysis first esti-
mates the probability of each outcome by GWG, controlling
for pre-pregnancy BMI category, and the associated
expected number of QALYs lost over the lifetime of the
mother and child. The analysis then calculates the total
expected QALYs lost by GWG and BMI (Table S2 and Fig.
S1), which we merged with our data to obtain expected
QALYs lost for each participant in the study (rounded to the
nearest kg). Since the IOM report only calculates QALYs
lost for GWG between 0 and 30 kg, we set GWG to 0 kg for
women with negative GWG (n= 5) and to 30 kg for women
with GWG > 30 kg (n= 2). We interpreted the difference in
QALYs lost between intervention and control groups as the
QALYs gained as a result of the intervention.
Incremental cost-effectiveness ratios (ICERs) were cal-
culated as cost per QALY gained, cost per kg of GWG
avoided, cost per case of excessive GWG averted and cost
per case of LGA averted. Non-parametric bootstrapping
using 5000 resamples was used to characterise uncertainty,
which were plotted using cost-effectiveness planes and cost-
effectiveness acceptability curves (CEAC). Cost-
effectiveness planes plot the bootstrapped pairs, with the
difference in effect on the x-axis and the difference in cost
on the y-axis for the intervention compared with the control.
The CEACs represent the probability that the intervention is
cost-effective, compared with the control, across a range of
willingness-to-pay ratios up to €45,000 per QALY, which is
Ireland’s official threshold [22]. The National Institute for
Health and Care Excellence (NICE) consider that UK-based
interventions that cost the National Health Service less than
£20,000 per QALY gained are cost effective [23].
Sensitivity analysis
To evaluate the robustness of our findings, we conducted a
sensitivity analysis using a per-protocol analysis, in which
participants were excluded if they did not attend all three
consultation visits. We re-calculated ICERs for all outcomes
and compared with our base-case results.
Results
Sample size
Five hundred and sixty-five women were recruited into the
PEARs trial and were randomly allocated to receive either
the ‘healthy lifestyle package’ or standard care. Nineteen
women had no information on delivery costs (ten in control,
nine in the intervention group): two had congenital or foetal
anomalies, four had miscarriages, eight did not return to the
hospital for delivery, and five had missing cost data most
likely due to error in assignment of hospital ID numbers.
Two hundred and six women (99 in the control and 107 in
the intervention groups) were missing gestational weight
gain data as a result of not appearing at the antenatal
appointment when it was measured. Twenty-four women
were missing infant size data (13 in the control and 11 in the
intervention). Our analyses included all available cases.
There were no significant differences between the inter-
vention group (n= 278) and the control group (n= 287) in
demographic characteristics at baseline (Table 1). There
were also no differences in baseline characteristics between
women with recorded gestational weight gain compared to
the full sample (Table 1).
PEARs effectiveness
The proportion of women who developed GDM did not
differ between the two groups [13]. Women in the inter-
vention group gained significantly less weight compared
with women in the control group (11.3 kg vs 12.6 kg, P=
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0.03). Women in the intervention group were also less
likely to exceed IOM GWG guidelines (50.9% vs 63.8%,
P= 0.01). When we converted absolute GWG to QALYs
lost, women in the intervention group lost fewer QALYs,
though the difference was not statistically significant (2.75
vs 2.85, P= 0.38). Finally, infants of mothers in the inter-
vention group were significantly less likely to be born LGA
than infants born to mothers in the control group (4.1% vs
8.7%, P= 0.03).
Costs
The cost associated with providing the mobile health
intervention was €152 per person (Table 2). There were no
significant differences across intervention and control
groups in mean cost of antenatal admissions (P= 0.42),
delivery costs (P= 0.63) or total health care utilisation
(P= 0.43). Total cost of the intervention including health
care utilisation was slightly higher in the intervention group,
though this difference was not statistically significant
(P= 0.08).
Cost-effectiveness
The ICER for QALYs was €2914 per QALY gained
(Table 3). More than 77% of bootstrap pairs were located in
the northeast (NE) quadrant, indicating that the PEARs
intervention is likely to be more expensive and more
effective with regards to QALYs than usual care. At a
threshold of €20,000 per QALY, the probability that PEARs
is cost-effective is 77% (Fig. 1), while at €45,000 per
QALY, the probability is 79%. The ICER for GWG was
€209 per kg of weight avoided and the ICERs for excessive
GWG and LGA were €2117 and €5911 per case averted,
respectively (Table 3). 95% or more of bootstrap pairs were
located in the NE quadrant for these three outcomes. The
CEAC for kg of GWG avoided reached a confidence level
of 95% at €905, indicating that if one is willing to pay a
maximum of an additional €905 per kg of GWG avoided,
there is a 95% probability that the intervention is cost-
effective (Fig. 2). The CEAC for case of LGA averted
reached a confidence level of 95% at €25,737 (Fig. 3). The
CEAC for case of excessive GWG averted reached a con-
fidence level of 95% at €7090.
Sensitivity analysis
Seventy-two participants were excluded in the per-protocol
analysis (32 in the control group, 40 in the intervention
group). Results of average costs of health care utilisation in
the per-protocol analysis were similar to the base-case
analysis (Table S3). Cost of antenatal care and delivery was
similar in the intervention and control groups (Table S3).
Results on cost-effectiveness were very similar to the base-
case analysis, albeit with slightly lower ICERs (Table 3).
Discussion
Main findings
This study contributes to our understanding of the costs and
consequences of a lifestyle intervention for prevention of
GDM; in particular, we are the first study to examine
whether using a mobile phone-based programme can be a
cost-effective way of improving maternal and infant
Table 1 Baseline characteristics
of the PEARs cohort.






All (n= 565) n= 359
Age—years 32.8 ± 4.6 32.2 ± 4.2 32.5 ± 4.4 32.4 ± 4.4
Primiparous—no. (%) 138 (49.6) 153 (53.3) 291 (51.5) 181 (50.4)
Body mass index category—no. (%)
Overweight, 25–29.9 kg/m2 184 (66.2) 195 (67.9) 379 (67.1) 243 (67.7)
Obese class I, 30–34.9 kg/m2 71 (25.5) 73 (25.4) 144 (25.5) 90 (25.1)
Obese class II, ≥35 kg/m2 23 (8.3) 19 (6.6) 42 (7.4) 26 (7.2)
Educational attainment—no. (%)
Some 2nd-level 7 (2.7) 6.0 (2.2) 13 (2.4) 9 (2.6)
Completed 2nd-level 35 (13.4) 35 (12.6) 70 (13.0) 47 (13.6)
Some 3rd-level 67 (25.6) 46 (16.6) 113 (21.0) 72 (20.9)
Completed 3rd-level 153 (58.4) 190 (68.6) 343 (63.6) 217 (62.9)
Ethnicity is white—no. (%) 257 (94.8) 255 (91.1) 512 (92.3) 324 (92.1)
Age missing for four control and seven intervention participants. Education missing for 10 control and 16
intervention participants. Ethnicity missing or unspecified for seven control and seven intervention
participants.
Plus–minus values are means ± standard deviation, GWG gestational weight gain.
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outcomes among pregnant women with an elevated BMI.
Our results indicate that the cost of inpatient and outpatient
maternal care and delivery did not significantly differ
between the treatment and control groups at a threshold of
P < 0.05, even when the cost of the intervention was
included. This is important given the clinical benefits
observed in terms of reducing GWG and a reduced risk of
LGA. Assuming a ceiling ratio of €45,000, the probability
that the intervention was cost‐effective was 79% based on
QALYs, indicating that the intervention may be cost-
effective. The cost per LGA case averted was €5911, while
the cost of avoiding an additional kilogram of GWG was
€209 and the cost per case of excess GWG averted was
€2117. As of yet, no detailed analysis of the health effects
or costs saved from reduction in risk of LGA or macrosomia
exist, which would provide guidance as to a reasonable
willingness-to-pay threshold for this outcome.
The 13% point reduction in risk of excessive GWG
observed in this study is clinically relevant as women who
gain weight in excess of the IOM recommendations are at
increased risk of negative health outcomes, as are their
children [21]. Reducing GWG is an important public health
goal as, in Ireland, over half of women with an elevated
BMI gain excessive weight during pregnancy [2, 24].
Reducing GWG could provide substantial savings to the
health care system by reducing a woman’s risk of future
weight retention [25, 26] and lifetime risk of obesity and
type 2 diabetes [6, 27]. In addition, infants born LGA, for
which excessive GWG is a risk factor independent of
maternal BMI [28], are more likely to be obese themselves
throughout the life course [4, 5, 29], and are more likely to
develop both type 1 and type 2 diabetes [30, 31], which
increases their lifetime medical costs [32, 33]. Thus, the
PEARs intervention has the potential to result in long-term
Table 2 Cost of the PEARs
intervention and health care
utilisation per person (all costs
in 2017 euro, €).
Intervention Control Difference (SE) P value
Cost item Mean (SD) n Mean (SD) n
Intervention costs
Mobile health applicationa 71.94 278 – – – N/A
Consultation visit 1b 60.28 278 – – – N/A
Consultation visit 2b 7.54 278 – – – N/A
Consultation visit 3b 9.74 278 – – – N/A
Consultation emailsc 1.84 278 – – – N/A
Text reminders for visitsc 0.48 278 – – – N/A
Total intervention cost per person 151.82
Health care utilisation costs
Average antenatal admissions costs 430 (913) 269 374 (706) 276 56 (69) 0.42
Delivery costs
Caesarean+ CSCC 7198 (3950) 17 6879 (2593) 14 319 (1230) 0.80
Caesarean -CSCC 4782 (91) 56 4765 (0) 60 17 (12) 0.14
Vaginal+OR PR+CSCC 4029 (0) 2 4029 (0) 2 0 1
Vaginal+OR PR -CSCC 3036 (0) 4 3036 (0) 3 0 1
Vaginal 2320 (50) 190 2316 (0) 198 4 (4) 0.31
Average delivery costs 3164 (1739) 269 3097 (1446) 276 73 (137) 0.63
Total health care utilisation cost
per person
3593 (1986) 269 3471 (1648) 276 122 (154) 0.43
Total cost per person, intervention+
health care utilisation
3745 (1986) 3471 (1648) 274 (154) 0.08
CSCC Catastrophic or Severe Complication or Comorbidity, OR PR Operating Room or Procedure.
aThe total cost of the mobile health application was €20,000, which included both application and content
development. We divided total cost by the number of intervention participants.
bThe first consultation was with a nutritionist (hourly cost €30.14) and took ~2 h. The second consultation
was also with a nutritionist and took ~15 min. The third consultation was with an obstetrician (hourly cost
€38.94) and took ~15 min. Costs associated with these consultations were calculated based on the HSE
salary scales for these healthcare professionals, including social insurance, pension, and overheads. Details
are in the Table S3.
cA nutritionist was tasked with sending pre-prepared emails to intervention participants every two weeks
(17 h total) and with tracking the participants to remind them to attend their research-related visits (4.42 h
total). The cost per participant for these activities was estimated by dividing the total time by the number of
intervention participants.
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savings. However, our analysis is limited to the time period
from first antenatal care appointment to delivery and we are
not able to measure the reduction in health care costs in the
long-term for either mother or infant via reduced GWG. We
are therefore not able to determine whether the health care
service would see long-term savings as a result of this
intervention.
An important consideration of our analysis is the choice
of the health care system perspective, rather than a societal
perspective. A societal perspective would also take into
account participant costs, including travel costs, diet and
exercise costs, and opportunity costs. We chose the health
care system perspective for several reasons. First, it is
specified as the reference case perspective in both the
guidelines of the Health Information and Quality Authority
in Ireland and the NICE in the UK. This perspective
therefore facilitates comparison of cost-effectiveness across
economic evaluations of health interventions with different
health outcomes. Second, the long-run aim of this study
would be to integrate PEARs into routine maternity ser-
vices. In this case, participants would conduct their PEARs
visits during the course of their normal antenatal care, and
therefore would not incur extra travel costs or opportunity
costs for their time on these visits. The phone application
itself is able to be used at any time that is convenient for
participants, and therefore minimises opportunity costs for
women compared to other lifestyle interventions. It is pos-
sible, however, that participants would incur higher diet and
exercise costs. While the PEARs study was not designed to
measure these costs in detail, we do have some evidence
that these costs were not substantially increased for parti-
cipants. In their exit interview, participants were asked
whether they felt that their weekly grocery bill increased as
a result of the intervention, with responses on a 5-point
Likert scale from strongly agree to strongly disagree. Most
participants responded that their costs did not increase: 77%
of participants agreed or strongly agreed that their diet costs
did not increase as a result of the intervention, 11% did not
agree or disagree with the statement, and 11% believed that
their costs did increase. However, it is important to
acknowledge this limitation in that patient costs were not
considered in this analysis.
While there are many randomised trials evaluating the
effectiveness of lifestyle interventions for prevention of
GDM, few examine cost-effectiveness [10, 11, 34]. We
identified three trials with associated economic evaluations.
Similar to our results, none of the trials identified reported
significant effects on QALYs. The results reported in this
study on cost-effectiveness with respect to infant outcomes
were consistent with those observed in the NELLI trial in
Finland [35] and the LIMIT study in Australia [36]; both
trials focused on dietary and physical activity counselling.
However, FitFor2, a trial conducted in the Netherlands [37]
that focused solely on physical activity was both costlier
and less effective than other trials, suggesting that dietary
counselling in lifestyle interventions is an important aspect
of cost-effectiveness. Although the PEARs trial involved a
similar number of total contacts with the health care system
as the NELLI and LIMIT trials, PEARs participants had
access to a mobile phone application that allowed them to
access information on diet and exercise at any time. This
additional intervention component did not result in an
intervention that was costlier than others described in the
literature, but did result in a larger effect on GWG. Parti-
cipants in the PEARs trial used the app often: the median
(IQR) of total instances of use was 24 (8–72) and the
median (IQR) for instances of use per week was 1.75
(0.71–3.49). Consistent access to information, in
Table 3 Cost-effectiveness estimates of PEARs (all costs in euro, €).
Sample size ICER analysis Distribution on cost-
effectiveness plane (%)
Intervention Control Incremental cost Incremental effect ICER NE SE SW NW
Main analysis
QALYs gained 171 188 274 0.09 (−0.12 to 0.31) 2914 77.1 3.1 0.7 19.1
GWG (kg reduced) 171 188 274 1.3 (0.15–2.49) 209 95.0 3.8 0.0 1.1
Excessive GWG (risk reduced) 171 188 274 0.13 (0.03–0.23) 2117 95.7 3.8 0.0 0.5
LGA (risk reduced) 267 274 274 0.046 (0.01–0.09) 5911 94.9 3.8 0.1 1.3
Per protocol analysis
QALYs gained 154 172 210 0.12 (−0.10 to 0.34) 1723 77.0 9.2 1.3 12.5
GWG (kg reduced) 154 172 210 1.4 (0.18–2.6) 154 88.5 10.4 0.1 1.0
Excessive GWG (risk reduced) 154 172 210 0.15 (0.04–0.25) 1440 89.0 10.5 0.0 0.5
LGA (risk reduced) 233 248 210 0.046 (0.002–0.09) 4592 87.6 10.2 0.3 1.9
GWG gestational weight gain, LGA large-for-gestational-age, QALY Quality adjusted life year, ICER incremental cost-effectiveness ratio, NE
northeast, SE southeast, SW southwest, NW northwest.
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conjunction with regular meetings with health care staff,
may have improved GWG outcomes at a low cost to the
health care system. A randomised trial of a text messaging
intervention for pregnant women in Australia also found
significant reductions in GWG [38]. Lastly, a large pro-
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Fig. 1 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for quality-adjusted
life years (QALYs). The top
figure shows the difference in
QALYs gained on the x-axis and
the difference in cost on the y-
axis for the intervention
compared with the control. The
bottom figure represents the
probability that the intervention
is cost-effective, compared with
the control, for a given
willingness-to-pay ratio.
Cost-effectiveness of a mobile health-supported lifestyle intervention for pregnant women with an. . . 1005
development of the mobile application; the intervention
may be more cost-effective when considering scaling up its
use to a larger population.
It is possible that it is more effective in terms of health
outcomes to conduct an intervention pre-pregnancy with the
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Fig. 2 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for gestational weight
gain (GWG). The top figure
shows the difference in kg in
weight gain on the x-axis and the
difference in cost on the y-axis
for the intervention compared
with the control. The bottom
figure represents the probability
that the intervention is cost-
effective, compared with the
control, for a given willingness-
to-pay ratio.
1006 E. J. O’Sullivan et al.
pregnancy with a BMI within the normal range. This is
likely to be most beneficial in terms of QALYs; previous
research suggests that among women with a normal BMI,
increasing GWG does not lead to an increase in QALYs lost
to the same extent it does among women with an elevated
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Fig. 3 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for case of large-for-
gestational age (LGA). The top
figure shows the difference in
risk of LGA on the x-axis and
the difference in cost on the y-
axis for the intervention
compared with the control. The
bottom figure represents the
probability that the intervention
is cost-effective, compared with
the control, for a given
willingness-to-pay ratio.
Cost-effectiveness of a mobile health-supported lifestyle intervention for pregnant women with an. . . 1007
pregnancy and following them up over time would require
considerable time and such an intervention would likely be
very costly. Women typically do not access preconception
health services [39]; as such, a sustained period of increased
contact points with health care professionals—i.e. during
pregnancy—is still likely to be the most effective time to
intervene. An alternative to conducting an intervention pre-
pregnancy would be to conduct an intervention among
women with a BMI within the normal range with an aim of
limiting their GWG, which would reduce their risk of
beginning future pregnancies at an elevated BMI. A pro-
tocol for such a trial has been published [40].
Strengths and limitations
This analysis makes an important contribution to the lit-
erature as there is currently a dearth of cost-effectiveness
information available for lifestyle interventions to reduce
risk of GDM. If interventions are to be scaled-up and
implemented within health care systems, an understanding
of the costs and benefits is essential.
This study has limitations. First, costs were calculated
only from pregnancy to delivery; downstream medical costs
could substantially impact cost-effectiveness estimates. A
seven-year follow up of the NELLI trial found that the mean
cumulative cost of the intervention group was 30.6% lower
than in the usual care group; however, this difference was
not statistically significant [41]. Second, we considered the
health care system perspective in our evaluation to provide a
policy-relevant analysis. A societal perspective that includes
patient costs may impact on the cost-effectiveness results.
Third, we do not measure QALYs directly, but estimate
QALYs from secondary data. Modelling QALYs lost using
secondary data has several limitations. First, it introduces
uncertainty into our analysis because the link between GWG
and QALYs was estimated with available IOM data, the data
in that analysis were gathered from a variety of sources with
varying sample size, and the respondents in the IOM data
may not be representative of the participants in PEARs.
Second, the IOM analysis focused on several key endpoints
(infant mortality, postpartum weight retention, and child-
hood obesity) because these were deemed to be quantita-
tively important and reasonably estimated [21]. However,
other aspects of quality of life such as mental health, social
functioning, and pain would not be included in this analysis.
While measuring QALYs directly would be preferable, our
results are similar to those of three other lifestyle interven-
tion trials that used three different methods for measuring
QALYS —via the health-related quality of life (HRQoL)
15D questionnaire [35], via the SF36 health survey [36], and
via the EuroQol-5D questionnaire [37]. None found a sig-
nificant impact on QALYs and our point estimate lies in
between the estimates calculated in these studies.
Finally, the results of this study may not be generalisable
to other populations, where health care costs and phone
ownership usage may be different.
Conclusion
Providing a mobile health-supported lifestyle intervention to
pregnant women with an elevated BMI may be a cost-
effective way of improving maternal and infant health. For-
mative qualitative research exploring the factors influencing
dietary choices among pregnant women with an elevated BMI
will help inform future intervention development [42].
Additional research on the cost-effectiveness of lifestyle
interventions is needed to understand the mechanisms of cost-
effective interventions and the long-term costs and con-
sequences for both mother and child. It may be prudent to
conduct interventions aiming to increase the proportion of
women beginning pregnancy with a BMI within the normal
range. Such interventions may be more beneficial for both
maternal and infant health and more cost-effective.
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